Search PubMed⌕ Search

PubMed · 6969258

Second generation antidepressants.

Abstract

One approach to research into depressive illness includes a clinical pharmacotherapeutic tack such as the use of investigational drugs with defined pharmacological and biochemical activity. Using this research strategem, a variety of new compounds have been investigated in recent years all of which are unique chemically; all differ from the classic tricyclic-MAOI compounds. Animal pharmacology and neurochemical studies also show a profile which largely differs from the standard reference compounds. Their effects on central monoamine metabolism differ widely; some act pre- and others postsynaptically, some act by re-uptake inhibition, others by enhancing release, others are precursors, while still others are receptor agonists; some have no apparent central effect. The data, considered collectively and critically evaluated, suggest that many of the newer compounds used investigationally, because of their clinical efficacy, seriously question the involvement of monoamines as responsible for either the antidepressant effect of the standard psychotropic drugs or as etiopathogenic in the affective disorders. The classic animal screening profiles used for predicting antidepressant drug efficacy in man do not hold for many of these newer antidepressants. the animal-laboratory models need be revised and reoriented towards finding similar molecules that are devoid of the addling side effects and contraindications of the existing standard tricyclic-MAOI genre. The newer second generation antidepressants stand as a hallmark of progress in research and treatment with psychotropic drugs.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Shopsin. 1980. Second generation antidepressants.. https://searchpubmed.org/record/pubmed%3A6969258/second-generation-antidepressants

Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite Search PubMed by Indiciae: BibTeX · RIS.

KEEP EXPLORING

Related citations

Inhibition of astroglial inwardly rectifying Kir4.1 channels by a tricyclic antidepressant, nortriptyline.

The inwardly rectifying K(+) (Kir) channel Kir4.1 is responsible for astroglial K(+) buffering. We examined the effects of nortriptyline, a tricyclic antidepressant (TCA), on Kir4.1 channel currents heterologously expressed in HEK293T cells, using a whole-cell patch-clamp technique. Nortriptyline (3-300 microM) reversibly inhibited Kir4.1 currents in a concentration-dependent manner, whereas it marginally affected neuronal Kir2.1 currents. The inhibition of Kir4.1 channels by nortriptyline depended on the voltage difference from the K(+) equilibrium potential (E(K)), with greater potency at more positive potentials. Blocking kinetics of the drug could be described by first-order kinetics, where dissociation of the drug slowed down and association accelerated as the membrane was depolarized. The dissociation constant (K(d)) of nortriptyline for Kir4.1 inhibition was 28.1 microM at E(K). Other TCAs, such as amitriptyline, desipramine, and imipramine, also inhibited Kir4.1 currents in a similar voltage-dependent fashion. This study shows for the first time that nortriptyline and related TCAs cause a concentration-, voltage-, and time-dependent inhibition of astroglial K(+)-buffering Kir4.1 channels, which might be involved in therapeutic and/or adverse actions of the drugs.

Antidepressive Agents, Tricyclic↗